What's happened
Recent studies reveal that stopping GLP-1 weight loss injections leads to significant weight regain, with only 25% of initial weight loss maintained after 60 weeks. A new oral pill, orforglipron, shows promise but has higher side effects. Experts warn of potential health risks if regained weight is mainly fat.
What's behind the headline?
The studies underscore a critical challenge in obesity pharmacotherapy: sustained weight loss remains elusive once treatment stops. The Cambridge research indicates that while some weight loss can be maintained, most individuals regain a substantial portion, primarily as fat, which could worsen health outcomes. The findings highlight the need for better guidelines and combined approaches, including diet and exercise, to sustain benefits. The US veteran study suggests these drugs also reduce substance misuse, adding a potential dual benefit. However, the higher discontinuation rates with orforglipron due to side effects raise questions about its long-term viability. Overall, the story reveals that pharmacological solutions alone are insufficient for lasting weight management and that comprehensive, personalized strategies are essential.
What the papers say
Sky News reports that Cambridge researchers found most patients regain 60% of lost weight after stopping GLP-1 injections, with concerns about fat versus lean mass. The Independent emphasizes that only 25% of weight loss is sustained long-term, warning about health risks if regained weight is mainly fat. Both sources highlight the need for further research into the composition of weight regain and improved treatment guidelines. The Guardian discusses the promising results of Eli Lilly's oral GLP-1 pill, orforglipron, which outperformed semaglutide in weight loss and blood sugar control but noted higher side effects and the need for longer-term safety data. Business Insider underscores Lilly's competitive edge over Novo Nordisk with this new pill, potentially transforming obesity treatment. Overall, the articles collectively illustrate the ongoing evolution of pharmacotherapy in obesity, balancing efficacy, side effects, and long-term management challenges.
How we got here
GLP-1 receptor agonists like semaglutide and tirzepatide are used for weight loss and diabetes management. Originally developed for type 2 diabetes, these drugs mimic the hormone GLP-1 to regulate blood sugar and suppress appetite. Their use for obesity has expanded, but concerns about long-term effects and weight regain after cessation are emerging from recent research.
Go deeper
More on these topics
-
Naveed Amjid Sattar FMedSci FRCPath FRCPGlas FRSE is a Scottish medical researcher and Professor of Metabolic Medicine at the Institute of Cardiovascular & Medical Sciences at the University of Glasgow, as well as an Honorary Consultant in Metabolic M
-
The University of Cambridge is a collegiate research university in Cambridge, United Kingdom. Founded in 1209 and granted a royal charter by King Henry III in 1231, Cambridge is the second-oldest university in the English-speaking world and the world's fo